Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gut microbial dysbiosis after traumatic brain injury modulates the immune response and impairs neurogenesis.
Celorrio M, Abellanas MA, Rhodes J, Goodwin V, Moritz J, Vadivelu S, Wang L, Rodgers R, Xiao S, Anabayan I, Payne C, Perry AM, Baldridge MT, Aymerich MS, Steed A, Friess SH. Celorrio M, et al. Among authors: aymerich ms. Acta Neuropathol Commun. 2021 Mar 10;9(1):40. doi: 10.1186/s40478-021-01137-2. Acta Neuropathol Commun. 2021. PMID: 33691793 Free PMC article.
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
Celorrio M, Fernández-Suárez D, Rojo-Bustamante E, Echeverry-Alzate V, Ramírez MJ, Hillard CJ, López-Moreno JA, Maldonado R, Oyarzábal J, Franco R, Aymerich MS. Celorrio M, et al. Among authors: aymerich ms. Brain Behav Immun. 2016 Oct;57:94-105. doi: 10.1016/j.bbi.2016.06.010. Epub 2016 Jun 16. Brain Behav Immun. 2016. PMID: 27318096
Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.
Elgueta D, Aymerich MS, Contreras F, Montoya A, Celorrio M, Rojo-Bustamante E, Riquelme E, González H, Vásquez M, Franco R, Pacheco R. Elgueta D, et al. Among authors: aymerich ms. Neuropharmacology. 2017 Feb;113(Pt A):110-123. doi: 10.1016/j.neuropharm.2016.09.028. Epub 2016 Sep 28. Neuropharmacology. 2017. PMID: 27693549
GPR55: A therapeutic target for Parkinson's disease?
Celorrio M, Rojo-Bustamante E, Fernández-Suárez D, Sáez E, Estella-Hermoso de Mendoza A, Müller CE, Ramírez MJ, Oyarzábal J, Franco R, Aymerich MS. Celorrio M, et al. Among authors: aymerich ms. Neuropharmacology. 2017 Oct;125:319-332. doi: 10.1016/j.neuropharm.2017.08.017. Epub 2017 Aug 12. Neuropharmacology. 2017. PMID: 28807673
The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia.
Rojo-Bustamante E, Abellanas MA, Clavero P, Thiolat ML, Li Q, Luquin MR, Bezard E, Aymerich MS. Rojo-Bustamante E, et al. Among authors: aymerich ms. Neurobiol Dis. 2018 Oct;118:64-75. doi: 10.1016/j.nbd.2018.06.019. Epub 2018 Jun 21. Neurobiol Dis. 2018. PMID: 29936234
58 results